Matinas BioPharma Holdings (MTNB) Operating Expenses (2013 - 2026)
Matinas BioPharma Holdings (MTNB) posted quarterly Operating Expenses of $1.9 million for Q1 2026, down 0.51% year-over-year from $1.9 million in Q1 2025, and up 21.0% quarter-over-quarter from $1.6 million in Q4 2025.
Matinas BioPharma Holdings (MTNB) Operating Expenses (2013 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Operating Expenses for 14 consecutive years, with $1.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses fell 0.51% year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $7.0 million (down 66.32% YoY), while the FY2025 annual figure was $7.0 million, down 71.7% from the prior year.
- Operating Expenses advanced to $1.9 million in Q1 2026 per MTNB's latest filing, from $1.6 million in the prior quarter.
- Across five years, Operating Expenses topped out at $8.5 million in Q4 2024 and bottomed at $1.6 million in Q3 2025.
- Historically, Operating Expenses has averaged $5.1 million across 5 years, with a median of $5.9 million in 2024.
- Annual changes were most pronounced in 2022 — Operating Expenses surged 45.9% — and 2025, when it plunged 81.11%.
- Matinas BioPharma Holdings' Operating Expenses stood at $6.5 million in 2022, then decreased by 10.03% to $5.9 million in 2023, then soared by 43.86% to $8.5 million in 2024, then slumped by 81.11% to $1.6 million in 2025, then grew by 21.0% to $1.9 million in 2026.
- Business Quant data shows MTNB's Operating Expenses at $1.9 million in Q1 2026, $1.6 million in Q4 2025, and $1.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Matinas BioPharma Holdings | 1.19 Mn | 375,426.61 | - | 1.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.56 Mn |
| Mar 31, 2026 | 1.94 Mn |
| Dec 31, 2025 | 1.60 Mn |
| Sep 30, 2025 | 1.58 Mn |
| Jun 30, 2025 | 1.84 Mn |
| Mar 31, 2025 | 1.95 Mn |
| Dec 31, 2024 | 8.47 Mn |
| Sep 30, 2024 | 4.38 Mn |
| Jun 30, 2024 | 5.84 Mn |
| Mar 31, 2024 | 5.90 Mn |
| Dec 31, 2023 | 5.89 Mn |
| Sep 30, 2023 | 6.13 Mn |
| Jun 30, 2023 | 6.16 Mn |
| Mar 31, 2023 | 6.68 Mn |
| Dec 31, 2022 | 6.54 Mn |
| Sep 30, 2022 | 6.53 Mn |
| Jun 30, 2022 | 6.99 Mn |
| Mar 31, 2022 | 7.72 Mn |
| Dec 31, 2021 | 6.71 Mn |
| Sep 30, 2021 | 6.88 Mn |